New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
15:26 EDTNYCB, DELL, CELG, EXPR, GMCRStocks with expanding option implied volatility; EXPR DELL GMCR CELG NYCB
News For EXPR;DELL;GMCR;CELG;NYCB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 26, 2015
16:33 EDTEXPRExpress note redemption adds 11c to FY15 earnings, says Nomura
Nomura expects the redemption of the 8.75% senior notes to add 11c to Express' FY15 earnings. In addition, the firm says its recent meeting with management highlighted better than expected holiday trends. The firm calls Express shares the cheapest in its retail coverage and keeps a Buy rating on the stock with a $16 price target.
15:14 EDTNYCBNew York Community Bancorp moves Q4 earnings release to January 29
Subscribe for More Information
14:54 EDTGMCRLavazza to sell portion of Keurig Green Mountain stake
Subscribe for More Information
January 23, 2015
13:19 EDTGMCRKeurig has negative read-through from Starbucks K-cup data, says Detwiler Fenton
Subscribe for More Information
13:07 EDTGMCRKeurig Green Mountain mentioned cautiously at Detwiler Fenton
Subscribe for More Information
10:50 EDTGMCRGreen Mountain Coffee calls active on renewed takeover chatter
Green Mountain Coffee January weekly 142 and 145 calls are active on total call volume of 3,200 contracts (600 puts). January weekly call option implied volatility is at 38, February is at 54, March is at 43; compared to its 26-week average of 42 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:37 EDTGMCRRumor: Keurig Green Mountain moves up on renewed takeover chatter
Shares of Keurig Green Mountain (GMCR) are moving higher on speculation Coca-Cola (KO) may acquire the rest of the company.
07:21 EDTCELGCelgene receives positive CHMP opinion for ABRAXANE
Subscribe for More Information
January 22, 2015
10:03 EDTGMCROn the Fly: Analyst Downgrade Summary
Subscribe for More Information
09:39 EDTGMCRKeurig Green Mountain downgraded to Neutral at Consumer Edge Research
January 21, 2015
10:01 EDTEXPROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:36 EDTCELGCelgene price target raised to $139 from $115 at RW Baird
Baird raised its price target on Celgene to $139 from $115 following last week's guidance from the company. Baird reiterated its Outperform rating on Celgene shares.
07:08 EDTEXPR, EXPRExpress downgraded to Sell from Buy at CLSA
CLSA downgraded Express to Sell from Buy following the announcement that buyout talks with private-equity firm Sycamore Partners have ended and expectations apparel trends will remain weak into FY16. Price target lowered to $12.
January 20, 2015
13:08 EDTEXPROn The Fly: Midday Wrap
Subscribe for More Information
10:33 EDTEXPR1981 Investments reports 9.8% stake in Express, intends to review investment
Subscribe for More Information
10:21 EDTEXPRExpress weakness a buying opportunity, says Mizuho
Subscribe for More Information
09:11 EDTEXPROn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTEXPRExpress, Sycamore Partners announce termination of discussions
Subscribe for More Information
08:07 EDTEXPRExpress, Sycamore Partners announce termination of discussions
Subscribe for More Information
January 16, 2015
09:11 EDTCELGCelgene says oral Otezla approved by European Commission in 2 indications
Celgene International, a wholly-owned subsidiary of Celgene Corporation, announced that the European Commission has granted marketing authorisation for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications: For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light. Alone or in combination with Disease Modifying Antirheumatic Drugs, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. The marketing authorization is based on efficacy and safety data from two Phase III programs, ESTEEM AND PALACE, which demonstrate a maintained clinical response among patients with psoriasis and psoriatic arthritis treated with OTEZLA through 52 weeks, across multiple endpoints. The EC decision follows the positive opinion issued by the Committee for Medicinal Products for Human Use in November 2014.12 OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use